{"filing":{"accession_number":"0001193125-26-308921","cik":"0001227636","ticker":"STIM","company_name":"Neuronetics, Inc.","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"d226320d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1227636/000119312526308921/d226320d8k.htm"},"events":[{"id":18793,"run_id":16908,"accession_number":"0001193125-26-308921","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.8,"summary":"Nir Naor was appointed as Executive Vice President and Chief Financial Officer effective July 23, 2026, with a compensation package including $480,000 base salary and a 500,000 RSU inducement grant. The appointment reflects the company's focus on strengthening financial oversight with an executive bringing 20+ years of finance and life sciences experience.","company_name":"Neuronetics, Inc.","ticker":"STIM","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17708,"accession_number":"0001193125-26-308921","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two executive changes: the appointment of Nir Naor as Executive Vice President and Chief Financial Officer effective July 23, 2026, and the departure of W. Andrew Macan as Executive Vice President, Chief Legal Officer, and Corporate Secretary effective August 15, 2026. While both events are disclosed, the primary focus and emphasis of the Item 5.02(c) section and the press release centers on Naor's appointment, with extensive detail on his qualifications, compensation package (including $480,000 base salary and 500,000 RSU grant), and strategic importance to the company. Macan's departure is disclosed in Item 5.02(b) with separation terms but receives less narrative emphasis. The appointment of a CFO with significant life sciences and medtech experience is material to investors assessing management capability and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:11:49.987953+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17709,"accession_number":"0001193125-26-308921","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on the appointment of Nir Naor as Chief Financial Officer effective July 23, 2026, with detailed background on his 20+ years of finance and life sciences experience and a material inducement grant of 500,000 restricted stock units. While the filing also mentions Cory Anderson's promotion and Andrew Macan's departure, the primary focus and lead announcement is Naor's CFO appointment, making this an executive appointment event. The materiality is clear given the CFO role's importance and the substantial equity inducement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:11:49.987953+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17708,"accession_number":"0001193125-26-308921","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two executive changes: the appointment of Nir Naor as Executive Vice President and Chief Financial Officer effective July 23, 2026, and the departure of W. Andrew Macan as Executive Vice President, Chief Legal Officer, and Corporate Secretary effective August 15, 2026. While both events are disclosed, the primary focus and emphasis of the Item 5.02(c) section and the press release centers on Naor's appointment, with extensive detail on his qualifications, compensation package (including $480,000 base salary and 500,000 RSU grant), and strategic importance to the company. Macan's departure is disclosed in Item 5.02(b) with separation terms but receives less narrative emphasis. The appointment of a CFO with significant life sciences and medtech experience is material to investors assessing management capability and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:11:49.987953+00:00","company_name":"Neuronetics, Inc.","ticker":"STIM","filing_date":"2026-07-20"},{"id":17709,"accession_number":"0001193125-26-308921","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on the appointment of Nir Naor as Chief Financial Officer effective July 23, 2026, with detailed background on his 20+ years of finance and life sciences experience and a material inducement grant of 500,000 restricted stock units. While the filing also mentions Cory Anderson's promotion and Andrew Macan's departure, the primary focus and lead announcement is Naor's CFO appointment, making this an executive appointment event. The materiality is clear given the CFO role's importance and the substantial equity inducement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:11:49.987953+00:00","company_name":"Neuronetics, Inc.","ticker":"STIM","filing_date":"2026-07-20"}]}